ArticleEye (London, England)2025
Ocular manifestations of patients with extranodal NK/T-cell lymphoma.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsTo investigate the ocular symptoms and characteristics exhibited by extranodal NK/T-cell lymphoma (ENKTL) patients.
methodsOne hundred sixty-eight patients with mature T/Natural Killer-cell Lymphoma (MTNKL) were recruited in this study, among whom 107 cases were ENKTL patients. A retrospective analysis was conducted on 12 of these ENKTL patients who had ocular symptoms. Results of ophthalmic and systemic auxiliary examinations, disease progression, and prognosis were documented.
resultsOcular symptoms occurred in bilateral eyes (n = 4) and unilateral eyes (n = 8). The average interval from the diagnosis of ENKTL to the onset of ocular symptoms was 18.1 (±20.8) months. According to the ocular symptoms and auxiliary examinations, eight patients had ocular adnexal symptoms only, and four patients had intraocular symptoms only. All patients exhibited impaired vision. After receiving combined treatment with systemic chemotherapy, radiotherapy, and local ocular therapy, six patients died during the follow-up, and the median survival time from diagnosis was 17 (range: 2-45) months. Among the surviving six patients, five out of seven eyes had poor visual prognoses lower than hand motion (HM), while two maintained a visual acuity of 20/25.
conclusionIn this study, the ocular presentations can be easily confounded with conditions such as uveitis or orbital cellulitis, necessitating vigilant clinical differentiation. To date, the visual prognoses of ENKTL patients with ocular symptoms remain regrettably poor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.